Modern immunology and therapeutic discovery rely on high-quality CD4 proteins that preserve native extracellular domain structure and deliver consistent, biologically relevant interactions.
Conigen’s recombinant CD4 is engineered to maintain native-like conformation of the D1-D4 ectodomain, enabling accurate binding to MHC class II, HIV gp120, and CD4-targeting antibodies.
These bioactive CD4 dimers are produced in HEK293 cells and validated for ELISA and SPR.
Each lot is QC’d for antibody and ligand binding to ensure reproducibility.
Conigen’s CD4 dimer is Fc-free providing enhanced avidity with reduced assay interference for clearer, more reliable data.
Offered in human and rhesus macaque species and available in His, His-Avi, and biotinylated formats, Conigen’s recombinant CD4 supports applications ranging from immuno-oncology and infectious disease research to antibody discovery and characterization.
Start your next breakthrough with Conigen’s recombinant CD4.
